Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.
Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. Journal Of The National Comprehensive Cancer Network 2020, 19: 1-4. PMID: 32871558, PMCID: PMC9730290, DOI: 10.6004/jnccn.2020.7610.Peer-Reviewed Original ResearchErythrocyte-stimulating agentsHematopoietic growth factorsGrowth factorSARS-CoV-2 infectionPandemic SARS-CoV-2 infectionGranulocyte colony-stimulating factorColony-stimulating factorTreatment of cancerThrombopoietin mimeticsHigh riskSuch growth factorsStimulating agentsPatientsCancerCOVID-19 eraCOVID-19 pandemicInfectionHigh-risk environmentsNeutropeniaThrombocytopeniaMorbidityChemotherapyFactorsAnemiaGroup